PD-1

Synonyms

Programmed cell death protein 1, CD279, hPD-1, PDCD1, Programmed Cell Death 1, Systemic Lupus Erythematosus Susceptibility 2, Protein PD-1, PD1, Programmed Cell Death 1 Protein, CD279 Antigen, HPD-L, HSLE1, SLEB2, PD-1, Programmed Cell Death 1 Receptor,

Description

Programmed cell death protein 1 is a protein on the surface of cells that has a role in regulating the immune system's response to the cells of the human body by down-regulating the immune system and promoting self-tolerance by suppressing T cell inflammatory activity. This prevents autoimmune diseases, but it can also prevent the immune system from killing cancer cells.Inhibitory receptor on antigen activated T-cells that plays a critical role in induction and maintenance of immune tolerance to self . Delivers inhibitory signals upon binding to ligands CD274/PDCD1L1 and CD273/PDCD1LG2 . Following T-cell receptor (TCR) engagement, PDCD1 associates with CD3-TCR in the immunological synapse and directly inhibits T-cell activation. Suppresses T-cell activation through the recruitment of PTPN11/SHP-2: following ligand-binding, PDCD1 is phosphorylated within the ITSM motif, leading to the recruitment of the protein tyrosine phosphatase PTPN11/SHP-2 that mediates dephosphorylation of key TCR proximal signaling molecules, such as ZAP70, PRKCQ/PKCtheta and CD247/CD3zeta.The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival . The interaction with CD274/PDCD1L1 inhibits cytotoxic T lymphocytes (CTLs) effector function . The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy .

KO Status

In Vitro

Drug Information

Launched drugs: 73
Drugs in clinical trials: 8
Latest Research Phase:Approved

Drug Name

Code

Phase

Company

Indications

Clinical Trials

MAX-2

Preclinical

Guangzhou Maxinovel Pharmaceiticals Co Ltd

Solid tumours

Recombinant human anti-PD-1 monoclonal antibody (Shiyao Group)

IND

Cspc Pharmaceutical Technology (Shijiazhuang) Co Ltd

MAX-5

Preclinical

Guangzhou Maxinovel Pharmaceiticals Co Ltd

Leukemia, Promyelocytic, Acute, Leukemia, Lymphocytic, Chronic, B-Cell

Dostarlimab

ANB-011, TSR-042, WBP-285

NDA/BLA

Anaptysbio

Ovarian Neoplasms, Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms, Endometrial Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms

JY-034

Preclinical

Solid tumours

MK-4280A

MK-4280A

IND

Merck Sharp & Dohme R & D (China) Co Ltd, Msd Ireland (Carlow) Merck Sharp & Dohme Corp

Solid tumours

Cemiplimab

REGN-2810, SAR-439684

Approved

Regeneron Pharmaceuticals Inc

Ovarian Neoplasms, Carcinoma, Renal Cell, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Basal Cell, Glioblastoma, Neoplasms, Hodgkin Disease, Prostatic Neoplasms, Hepatitis B, Diffuse Intrinsic Pontine Glioma, Peritoneal Neoplasms, Carcinoma, Squamous Cell, Endometrial Neoplasms, Fallopian Tube Neoplasms, Lymphoma, Glioma, Carcinoma, Non-Small-Cell Lung, Melanoma, Carcinoma, Hepatocellular, Neoplasm Metastasis, Uterine Cervical Neoplasms

Nivolumab Biosimilar

LY-01015

Preclinical

Luye Pharma

Neoplasms

Genolimzumab

GB-226, CBT-501

NDA/BLA

Genor Biopharma Co Ltd, Cbt

Lymphoma, B-Cell, Lymphoma, T-Cell, Peripheral, Carcinoma, Renal Cell, Microsatellite Instability, Sarcoma, Colorectal Neoplasms, Thymus Neoplasms, Thymoma, Neoplasms, Unknown Primary, Lymphoma, Lymphoma, Non-Hodgkin, Sarcoma, Alveolar Soft Part, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Carcinoma, Non-Small-Cell Lung

Prolgolimab

BCD-100

Approved

Biocad

Carcinoma, Non-Small-Cell Lung, Melanoma, Uterine Cervical Neoplasms

Penpulimab

AK-105

NDA/BLA

Zhongshan Akeso Biopharma Co Ltd

Head and Neck Neoplasms, Thoracic Neoplasms, Stomach Neoplasms, Neoplasms, Hodgkin Disease, Neuroendocrine Tumors, Nasopharyngitis, Bile Duct Diseases, Nasopharyngeal Carcinoma, Urologic Neoplasms, Colorectal Neoplasms, Carcinoma, Squamous Cell, Lung Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Carcinoma, Non-Small-Cell Lung, Adenocarcinoma

AK-123

AK-123, AK123

Preclinical

Zhongshan Akeso Biopharma Co Ltd

Neoplasms

MAX-6

Preclinical

Guangzhou Maxinovel Pharmaceiticals Co Ltd

Solid tumours

Camrelizumab

SHR-1210, INCSHR-1210, HR-301210

Approved

Suzhou Suncadia Biopharmaceuticals Co Ltd, Jiangsu Hengrui Medicine Co Ltd

Ovarian Neoplasms, Carcinoma, Bronchogenic, Esophageal Neoplasms, Stomach Neoplasms, Thoracic Neoplasms, Bronchial Neoplasms, Carcinoma, Renal Cell, Hodgkin Disease, Neoplasms, Carcinoma, Transitional Cell, Triple Negative Breast Neoplasms, Lung Diseases, Breast Neoplasms, Lymphoma, Extranodal NK-T-Cell, Nasopharyngeal Carcinoma, Respiratory Tract Neoplasms, Genital Neoplasms, Female, Urologic Neoplasms, Lung Neoplasms, Endometrial Neoplasms, Carcinoma, Squamous Cell, Esophageal Squamous Cell Carcinoma, Melanoma, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Uterine Cervical Neoplasms, Neoplasms by Site, Carcinoma, Hepatocellular

705

BSBA1, 705

Preclinical

Shenyang Sunshine Pharmaceutical Co Ltd

Neoplasms

Nivolumab

MDX-1106, ONO-4538, ono-0123, BMS-936558, BMS-936558-01

Approved

Bristol-Myers Squibb Company, Ono Pharmaceutical Co Ltd

Hematologic Neoplasms, Head and Neck Neoplasms, Ovarian Neoplasms, Bone Marrow Neoplasms, Solid tumours, Chondrosarcoma, Lymphoma, B-Cell, Kidney Neoplasms, Liver Neoplasms, Carcinoma, Merkel Cell, Carcinoma, Carcinoma, Renal Cell, Squamous Cell Carcinoma of Head and Neck, Stomach Neoplasms, Esophageal Neoplasms, Irritable Bowel Syndrome, Small Cell Lung Carcinoma, Carcinoma, Transitional Cell, Neoplasms, Glandular and Epithelial, Pancreatic Neoplasms, Hodgkin Disease, Adenocarcinoma of Lung, Clostridium Infections, Glioblastoma, Skin Neoplasms, Colonic Neoplasms, Sepsis, Triple Negative Breast Neoplasms, Urinary Bladder Neoplasms, Adrenocortical Carcinoma, Prostatic Neoplasms, Castration-Resistant, Mesothelioma, Multiple Myeloma, Breast Neoplasms, Microsatellite Instability, Sarcoma, Cholangiocarcinoma, Prostatic Neoplasms, Lymphoma, Mantle-Cell, Colorectal Neoplasms, Peritoneal Neoplasms, Urologic Neoplasms, Genital Neoplasms, Female, Hepatitis C, Esophageal Squamous Cell Carcinoma, Glioma, Lymphoma, Carcinoma, Squamous Cell, Lung Neoplasms, Endometrial Neoplasms, Fallopian Tube Neoplasms, Urogenital Neoplasms, Lymphoma, Non-Hodgkin, Melanoma, Carcinoma, Hepatocellular, Neoplasm Metastasis, Carcinoma, Non-Small-Cell Lung, Adenocarcinoma, Uterine Cervical Neoplasms, Neoplasms by Site

Toripalimab

JS-001, SO-001, TAB-001

Approved

Shanghai Junshi Biosciences Co Ltd, Suzhou Union Biopharm Biosciences Co Ltd

Solid tumours, Kidney Neoplasms, Stomach Neoplasms, Esophageal Neoplasms, Small Cell Lung Carcinoma, Carcinoma, Transitional Cell, Triple Negative Breast Neoplasms, Urinary Bladder Neoplasms, Neuroendocrine Tumors, Nasopharyngeal Carcinoma, Lymphoma, Carcinoma, Hepatocellular, Carcinoma, Non-Small-Cell Lung, Melanoma

Tislelizumab

BGB-A317

Approved

Beigene Ltd

Lymphoma, T-Cell, Peripheral, Lymphoma, B-Cell, Marginal Zone, Solid tumours, Esophageal Neoplasms, Stomach Neoplasms, Carcinoma, Transitional Cell, Lymphoma, Large B-Cell, Diffuse, Hodgkin Disease, Small Cell Lung Carcinoma, Breast Neoplasms, Lymphoma, Extranodal NK-T-Cell, Microsatellite Instability, Lymphoma, Follicular, Lymphoma, Mantle-Cell, Lymphoma, Lymphoma, T-Cell, Cutaneous, Esophageal Squamous Cell Carcinoma, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic, Lung Neoplasms, Carcinoma, Squamous Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Melanoma, Carcinoma, Hepatocellular, Carcinoma, Non-Small-Cell Lung

Sintilimab

IBI-308

Approved

Innovent Biologics (Suzhou) Co Ltd

Solid tumours, Recurrence, Esophageal Neoplasms, Hodgkin Disease, Lymphoma, Extranodal NK-T-Cell, Colorectal Neoplasms, Lung Neoplasms, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Melanoma, Uterine Cervical Neoplasms

REMD-288

REMD-288

Preclinical

Remd Biotherapeutics

Neoplasms

What's Next for KO Library?

Please stay tuned for the latest progress of KO Library. We are open to co-development programs of antibody therapeutics using our RenMab™-target-knockout mice.
Please contact our team if you are interested in learning more about KO Library or partnering opportunities.